Introduction & Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly associated with type 2 diabetes (T2D) and the screening for MASLD and liver fibrosis is currently recommended. We evaluated the correlation of liver fibrosis and steatosis parameters between a FibroScan® and a new ultrasound imaging point-of-care device: Hepatoscope™.

Methods: This is an interim analysis including the subgroup of participants with T2D and MASLD age 40-80 years, BMI <40 kg/m2 enrolled in an ancillary study of a prospective multicenter study in 3 diabetes clinics in France between Dec 2022 and Dec 2023 (NCT04435054). All participants underwent the same day liver stiffness measurement using vibration controlled transient elastography (VCTE) by FibroScan®, 2D-measurements of shear wave speed (2DTE) by Hepatoscope™, hepatic fat content assessment using controlled attenuation parameter (CAP) by FibroScan® and ultrasound attenuation (ATT) and backscattering coefficient (BSC) by Hepatoscope. The non-parametric spearman correlation coefficients between VCTE and 2DTE, and between CAP and ATT or BSC were assessed in participants with both valid VCTE and 2DTE.

Results: 130 participants (86% male) were included (mean age: 62.6 years, mean BMI: 31.7±3.7 kg/m2). Median liver parameters were as follows: VCTE: 6.5 ± 4.3 kPa, 2DTE: 6.2 ± 4.5 kPa, CAP: 313 ± 54 dB/m, ATT: 277 ±49 dB/m and BSC: -22.7±-5.3. 2DTE correlated strongly with VCTE (r2: 0.47, p<0,001). Likewise, ATT and BSC using Hepatoscope™ correlated significantly with CAP (r2: 0.54, p<0.001 and r2:0.61 p<0.001, respectively).

Conclusion: These preliminary data indicate that Hepatoscope™ 2DTE is significantly correlated with VCTE. It provides the proof of concept that liver assessment using the Hepatoscope™ could be used in diabetology for liver fibrosis and steatosis assessment. Further studies in larger cohort are needed to determine the cut-offs and diagnostic performance of the Hepatoscope™ in diabetology.

Disclosure

C. Caussy: Other Relationship; Echosens, E-scopics, Novo Nordisk. Consultant; Lilly Diabetes. Other Relationship; Gilead Sciences, Inc. Consultant; GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp. Advisory Panel; Corcept Therapeutics. B. Vergès: Consultant; Lilly Diabetes, Novo Nordisk A/S. Advisory Panel; Recordati. Consultant; AstraZeneca, Sanofi. B. Segrestin: None. A. Rouland: Other Relationship; Lilly Diabetes, Sanofi, Novo Nordisk. J. Petit: None. D. Delaunay: None. S. Charrière: Other Relationship; Novo Nordisk, Lilly Diabetes. Consultant; biomarin. Other Relationship; Amgen Inc., Novartis AG, Amarin Corporation. P. Moulin: Other Relationship; Novo Nordisk, Ionis Pharmaceuticals, Sanofi. Advisory Panel; ulktragenix. E. Disse: Board Member; Novo Nordisk. Consultant; Novo Nordisk, Lilly Diabetes, Sanofi, Rhythm Pharmaceuticals, Inc., Johnson & Johnson Medical Devices Companies.

Funding

E-scopics

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.